Loading
journalsJournal
Cancer immunology, immunotherapy
Cancer Immunology, Immunotherapy (CII) is a long-running Springer journal on how the immune system recognises cancer and how that can be turned into treatment. Read by tumour immunologists and immunotherapy clinicians.
Also called: Cancer immunology, immunotherapy : CIICancer Immunol ImmunotherCIICancer Immunology, Immunotherapy
Overview
Cancer Immunology, Immunotherapy (CII) is published by Springer and is affiliated with six cancer immunotherapy organisations: the Association for Cancer Immunotherapy (CIMT), the Canadian Cancer Immunotherapy Consortium, the Japanese Association for Cancer Immunology, the Network Italiano per la Bioterapia dei Tumori, the Spanish SEI-GEIT group and Cancer Immunotherapy and Immunomonitoring (CITIM). Its aims page states that since its inception in 1976 it has reported advances in tumour immunology, publishing broad-ranging ideas and reviews, results that extend or challenge established paradigms, and negative studies, across basic, translational and clinical research. NLM dates the present title to 1982, when it continued Cancer Immunology and Immunotherapy; it appears twelve times a year. DOAJ records it as fully open access since 2024 under CC BY and CC BY-NC-ND licences with an article processing charge, and anonymous peer review. Indexed in MEDLINE.
Publisher
Springer
Scope
cancer immunology
Access model
open access
Founded
1982
ISSN
0340-7004
meta analysis200760 citations
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
meta analysis200644 citations
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Alfredo Addeo
Head of Division, Oncology
Thoracic oncologyImmunotherapyMedical oncology
Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals.
David Fennelly
Clinical Director for Cancer Services, St Vincent's University Hospital and St Vincent's UCD Cancer Centre
Medical oncologyCancer services leadershipNational cancer strategy
Medical oncologist who is Clinical Director for Cancer Services at St Vincent's University Hospital and its UCD Cancer Centre in Dublin, Ireland's largest cancer care provider.
Michelle Xia (Xia Yu)
Founder, Chairwoman and CEO, Akeso
Bispecific antibodiesAntibody discoveryBiotech leadership
Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial.
meta analysisCancer immunology, immunotherapy 200760 citations
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
meta analysisCancer immunology, immunotherapy 200644 citations
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Similar pages
- TechnologyPSK (Krestin) mushroom polysaccharide as adjuvant therapy
Shares Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer, Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials.
- InstitutionGeneva University Hospitals (HUG)
- JournalJournal of immunotherapy
- JournalTargeted oncology
- JournalOncoimmunology
fronts
technologies
collections
people
key papers
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancerEfficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials